Detrusitol

How to order Detrusitol

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Detrusitol on Prescriptsy

Detrusitol is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Detrusitol is the UK brand name for tolterodine, an antimuscarinic medicine prescribed for the treatment of overactive bladder (OAB).

It is used to relieve symptoms of urinary urgency, increased urinary frequency, and urge incontinence in adults whose symptoms have not responded adequately to non-pharmacological measures such as bladder training and pelvic floor exercises.

Detrusitol is available as immediate-release tablets and as a modified-release capsule formulation (Detrusitol XL), both of which are prescription-only medicines (POM) in the United Kingdom.

Overactive bladder is one of the most common lower urinary tract conditions, estimated to affect between 12 and 17% of the adult population in the UK.

It occurs in both men and women and becomes more prevalent with increasing age.

The hallmark symptom is urinary urgency, defined as a sudden, compelling desire to pass urine that is difficult to defer.

This is often accompanied by increased daytime frequency (voiding more than eight times per day), nocturia (waking to pass urine one or more times at night), and urge incontinence (involuntary leakage of urine associated with urgency).

Despite being common, overactive bladder is frequently under-reported due to embarrassment, and it can profoundly affect quality of life, mental health, social participation, and work productivity.

This page provides a detailed clinical overview of Detrusitol, covering its mechanism of action, dosing, expected outcomes, side effects, safety warnings, and practical advice for patients in the UK.

Important safety information about Detrusitol

Before reading further, note the following key safety points.

• Detrusitol must not be taken by anyone with urinary retention, uncontrolled narrow-angle glaucoma, or myasthenia gravis.
• Antimuscarinic medicines can affect cognitive function, particularly in older adults. Discuss the risks and benefits with your prescriber, especially if you are over 65.
• Detrusitol may cause blurred vision and dizziness. Do not drive or operate machinery if affected.
• Stop Detrusitol and seek emergency care (call 999) if you are unable to pass urine, or if you develop swelling of the face, lips, or throat.
• Review your need for continued antimuscarinic treatment at least once a year with your GP or specialist.

Understanding overactive bladder

The bladder is a hollow muscular organ lined with smooth muscle called the detrusor.

During normal filling, the detrusor relaxes to accommodate increasing urine volume, while the urethral sphincter remains contracted to maintain continence.

When the bladder reaches a comfortable capacity, sensory signals travel via pelvic nerves to the brainstem micturition centre, generating a conscious urge to void.

In a healthy bladder, this urge can be deferred until a convenient time.

In overactive bladder, the detrusor contracts involuntarily during the filling phase, producing sudden urgency and, if the contraction is strong enough, incontinence.

These involuntary contractions are called detrusor overactivity and are mediated primarily by acetylcholine acting on muscarinic M2 and M3 receptors in the bladder wall.

The M3 receptor subtype is principally responsible for mediating detrusor contraction, while M2 receptors may play a modulatory role.

The cause of OAB is often idiopathic (no identifiable underlying pathology), but it can also be associated with neurological conditions such as multiple sclerosis, Parkinson's disease, stroke, and spinal cord injury.

In men, benign prostatic enlargement may contribute to or coexist with OAB symptoms. A thorough clinical assessment, including exclusion of urinary tract infection, is essential before treatment.

How Detrusitol works: mechanism of action

Tolterodine, the active substance in Detrusitol, is a competitive antagonist at muscarinic receptors.

It blocks acetylcholine from binding to M2 and M3 receptors on the detrusor muscle, thereby reducing the frequency and amplitude of involuntary detrusor contractions.

This allows the bladder to fill to a larger volume before the urge to void becomes compelling, reducing episodes of urgency, frequency, and urge incontinence.

Tolterodine demonstrates functional selectivity for the bladder over the salivary glands in vivo.

This means that at therapeutic doses, it reduces bladder contractility more effectively than it reduces saliva production, resulting in less dry mouth than older, less selective antimuscarinics such as oxybutynin.

This relative selectivity is a key clinical advantage.

Tolterodine is metabolised in the liver primarily by the cytochrome P450 enzyme CYP2D6 to form 5-hydroxymethyl tolterodine, an active metabolite that contributes to the overall antimuscarinic effect.

In patients who are CYP2D6 poor metabolisers (approximately 7% of the Caucasian population), tolterodine is metabolised by CYP3A4 instead, resulting in higher parent drug levels but a similar overall clinical effect due to reduced metabolite formation.

Clinical evidence and NICE guidance

The efficacy of tolterodine has been demonstrated in numerous randomised controlled trials.

Studies comparing tolterodine 2 mg twice daily (immediate-release) and 4 mg once daily (extended-release) with placebo showed significant reductions in daily micturition frequency, urgency episodes, and incontinence episodes.

The extended-release formulation achieved comparable efficacy to immediate-release tolterodine with a significantly lower incidence of dry mouth (approximately 23% versus 30 to 35% in clinical trials).

NICE guideline NG123 (Urinary incontinence and pelvic organ prolapse in women) recommends that pharmacological treatment for overactive bladder should be offered only after conservative measures (bladder training for at least 6 weeks, lifestyle advice including caffeine reduction, weight management, and fluid optimisation) have been tried.

When medication is indicated, NICE recommends either an antimuscarinic (such as tolterodine, solifenacin, or darifenacin) or a beta-3 agonist (mirabegron) as first-line pharmacological therapy.

The NICE guideline specifically highlights the cognitive risks associated with antimuscarinic medicines in older adults, referencing evidence that prolonged use may be associated with increased risk of dementia.

It advises clinicians to discuss these risks with patients, review treatment annually, and consider mirabegron as a potentially safer alternative in older or cognitively vulnerable patients.

Dosage and administration

Detrusitol immediate-release tablets are taken as 2 mg twice daily, approximately 12 hours apart, with or without food.

Detrusitol XL modified-release capsules are taken as 4 mg once daily, preferably at the same time each day.

The XL capsule should be swallowed whole and not crushed, chewed, or opened. The XL formulation is generally preferred for its convenience and improved tolerability profile.

If dry mouth, constipation, or other antimuscarinic side effects are troublesome, the dose may be reduced to 1 mg twice daily (immediate-release) or 2 mg once daily (XL) at the prescriber's discretion.

Dose reduction is also recommended for patients with significant hepatic impairment, severe renal impairment, or those taking potent CYP3A4 inhibitors.

An initial treatment review should take place after 4 to 6 weeks.

If there is no meaningful clinical improvement, the prescriber should reconsider the diagnosis, check compliance, and consider alternative treatment options.

Ongoing treatment should be reviewed at least annually, particularly in older patients.

Non-pharmacological treatments for overactive bladder

Detrusitol works best as part of a broader management strategy. Bladder training involves gradually increasing the interval between voids by using relaxation and distraction techniques to defer urgency.

A structured programme over 6 to 12 weeks can produce significant improvements, sometimes comparable to medication alone.

Pelvic floor muscle training, supervised by a specialist physiotherapist, strengthens the muscles that support the urethra and may reduce urgency and incontinence, particularly in women.

Lifestyle modifications include reducing caffeine intake (tea, coffee, cola, energy drinks), moderating alcohol consumption, adjusting fluid intake to avoid overhydration or dehydration, managing constipation, and achieving a healthy body weight.

These measures are recommended by NICE as first-line interventions before considering medication.

Side effects of Detrusitol

Common side effects

The most frequently reported side effect is dry mouth, occurring in approximately 10 to 15% of patients taking the XL formulation and 20 to 35% with immediate-release tablets.

Other common side effects include headache, dizziness, constipation, abdominal discomfort, dyspepsia, dry eyes, and blurred vision. Most of these are related to the antimuscarinic mechanism and are dose-dependent.

Uncommon and rare side effects

Uncommon side effects include urinary retention, drowsiness, nervousness, palpitations, peripheral oedema, weight gain, gastro-oesophageal reflux, and difficulty swallowing.

Rare side effects include confusion, hallucinations (especially in elderly patients), memory impairment, tachycardia, angioedema, and severe allergic reactions.

Cognitive adverse effects warrant particular attention in older patients, and any new confusion or memory problems during treatment should be reported to the prescriber promptly.

When to seek medical advice

Seek emergency medical attention (call 999 or attend A&E) if you are unable to pass urine, experience swelling of the face, lips, tongue, or throat, or develop difficulty breathing.

Contact your GP or NHS 111 if you experience persistent or worsening constipation, significant visual disturbance, confusion, hallucinations, or any new symptoms that concern you.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Cognitive effects in older adults

Antimuscarinic medicines including tolterodine have been associated with cognitive decline and an increased risk of dementia in observational studies of older adults.

The risk appears to be related to cumulative antimuscarinic burden and duration of use.

NICE recommends that clinicians discuss these potential risks with patients, particularly those over 65, and consider alternatives such as mirabegron.

Treatment should be reviewed at least annually, and if cognitive symptoms develop, antimuscarinic therapy should be reconsidered.

Urinary retention and bladder outlet obstruction

Antimuscarinics reduce the force of detrusor contraction and may worsen urinary retention in patients with bladder outlet obstruction, most commonly caused by benign prostatic enlargement in men.

A post-void residual volume measurement should be performed before initiating antimuscarinic treatment, and patients should be advised to seek medical attention if they experience increasing difficulty passing urine.

Gastrointestinal effects

Antimuscarinics reduce gastrointestinal motility and may worsen constipation, gastro-oesophageal reflux, and conditions such as gastroparesis. Patients with pre-existing constipation should be advised on adequate fluid and fibre intake and may require laxatives during treatment.

Glaucoma

Detrusitol is contraindicated in uncontrolled narrow-angle glaucoma. Patients with controlled narrow-angle or open-angle glaucoma may use Detrusitol with caution, but should inform their ophthalmologist.

How to get a Detrusitol prescription in the UK

Detrusitol is a prescription-only medicine. Your GP can prescribe it following a clinical assessment that includes symptom evaluation, bladder diary review, urinalysis, and assessment of post-void residual volume.

Referral to a specialist (urologist, urogynaecologist, or continence service) may be appropriate for patients whose symptoms do not respond to initial treatment, or when the diagnosis is uncertain.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) may also prescribe Detrusitol following a structured online consultation.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

When to seek further medical advice

Contact your GP or NHS 111 if your symptoms do not improve after 4 to 6 weeks of treatment, if you develop new urinary symptoms such as blood in the urine or pain on urination, or if you experience troublesome side effects.

Seek emergency care (call 999 or attend A&E) if you are unable to pass urine or develop signs of a severe allergic reaction.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Detrusitol XL 4 mg, Summary of Product Characteristics (EMC)
• Tolterodine tartrate, British National Formulary (BNF)
• NICE NG123: Urinary incontinence and pelvic organ prolapse in women
• NICE CKS: Urinary incontinence in women
• Urinary incontinence, NHS
• MHRA Yellow Card Scheme